Supernus Pharmaceuticals, Inc. (FRA:S49)

Supernus Pharmaceuticals Statistics

Total Valuation

FRA:S49 has a market cap or net worth of EUR 2.20 billion. The enterprise value is 2.00 billion.

Market Cap	2.20B
Enterprise Value	2.00B

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	57.34M
Shares Outstanding	n/a
Shares Change (YoY)	+0.54%
Shares Change (QoQ)	-0.16%
Owned by Insiders (%)	4.29%
Owned by Institutions (%)	101.91%
Float	54.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	17.30
PS Ratio	3.80
PB Ratio	2.46
P/TBV Ratio	8.42
P/FCF Ratio	36.56
P/OCF Ratio	35.99
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.41, with an EV/FCF ratio of 33.15.

EV / Earnings	-122.70
EV / Sales	3.41
EV / EBITDA	17.41
EV / EBIT	69.28
EV / FCF	33.15

Financial Position

The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.04.

Current Ratio	1.80
Quick Ratio	1.37
Debt / Equity	0.04
Debt / EBITDA	0.32
Debt / FCF	0.60
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -1.86% and return on invested capital (ROIC) is 1.96%.

Return on Equity (ROE)	-1.86%
Return on Assets (ROA)	1.52%
Return on Invested Capital (ROIC)	1.96%
Return on Capital Employed (ROCE)	3.08%
Revenue Per Employee	861,833
Profits Per Employee	-24,174
Employee Count	674
Asset Turnover	0.49
Inventory Turnover	1.06

Taxes

Income Tax	-1.38M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.70% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+15.70%
50-Day Moving Average	41.54
200-Day Moving Average	33.35
Relative Strength Index (RSI)	46.13
Average Volume (20 Days)	6

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.09

Income Statement

In the last 12 months, FRA:S49 had revenue of EUR 580.88 million and -16.29 million in losses. Loss per share was -0.29.

Revenue	580.88M
Gross Profit	516.18M
Operating Income	28.59M
Pretax Income	-17.67M
Net Income	-16.29M
EBITDA	101.37M
EBIT	28.59M
Loss Per Share	-0.29

Balance Sheet

The company has 239.63 million in cash and 35.98 million in debt, giving a net cash position of 203.66 million.

Cash & Cash Equivalents	239.63M
Total Debt	35.98M
Net Cash	203.66M
Net Cash Per Share	n/a
Equity (Book Value)	894.63M
Book Value Per Share	15.66
Working Capital	224.38M

Cash Flow

In the last 12 months, operating cash flow was 61.26 million and capital expenditures -957,985, giving a free cash flow of 60.30 million.

Operating Cash Flow	61.26M
Capital Expenditures	-957,985
Free Cash Flow	60.30M
FCF Per Share	n/a

Margins

Gross margin is 88.86%, with operating and profit margins of 4.92% and -2.80%.

Gross Margin	88.86%
Operating Margin	4.92%
Pretax Margin	-3.04%
Profit Margin	-2.80%
EBITDA Margin	17.45%
EBIT Margin	4.92%
FCF Margin	10.38%

Dividends & Yields

FRA:S49 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.54%
Shareholder Yield	-0.54%
Earnings Yield	-0.74%
FCF Yield	2.74%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:S49 has an Altman Z-Score of 4.52 and a Piotroski F-Score of 4.

Altman Z-Score	4.52
Piotroski F-Score	4